Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major bleeding, in patients with provoked VTE and enduring risk factors, ...
ELIQUIS® (apixaban) Demonstrated Superiority In Reducing A Composite Of Recurrent Venous Thromboembolism And All-Cause Death Without Increasing The Rate Of Major Bleeding Versus Placebo During One ...
Bristol-Myers Squibb and Pfizer announced the results of the Phase 3 AMPLIFY-EXT trial, which evaluated treatment with Eliquis (apixaban) over a one-year period compared to placebo for the prevention ...
Bristol-Myers Squibb and Pfizer announced results from the pre-specified secondary analysis of the Phase 3 AMPLIFY-EXT (Apixaban after the initial Management of PuLmonary embolIsm and deep vein ...
Rivaroxaban once daily and dabigatran twice daily showed evidence of lower thromboembolic rates. Apixaban 2.5 mg twice daily was associated with higher rates of ischemic stroke or systemic embolism ...
ATLANTA — Twelve months of treatment with apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) at either of two dosages, given after six to 12 months of anticoagulation to treat venous thromboembolism (VTE ...
Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — New data from the AUGUSTUS trial provide insight on the appropriate antithrombotic regimen after ...
In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control ...
Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major bleeding, in patients with provoked VTE and enduring risk factors, ...
Patients with A-fib and only one of the three dose-reduction criteria used in the ARISTOTLE trial—age 80 years or older, body weight 60 kg or less, and creatinine level 1.5 mg/dL or higher—have higher ...
Extended apixaban or dabigatran reduces recurrent VTE Extended anticoagulation with apixaban or dabigatran reduces recurrent VTE and mortality without increasing major bleeding. Level 1: Likely ...
DURHAM, NC — A secondary analysis of the ARISTOTLE trial supports using the standard 5-mg twice-daily dose of apixaban (Eliquis, Bristol-Myers Squibb) in patients with atrial fibrillation (AF) who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results